Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

The International Psoriasis Council (IPC) and the International Federation of Psoriatic Disease Associations (IFPA) announce an official partnership

IPC is excited to announce an official partnership with IFPA, a global organization made up of fifty-eight national psoriasis organizations representing the psoriatic disease community.

Our shared vision to improve access to quality care for people living with psoriasis and psoriatic arthritis worldwide will support our common efforts to provide educational information, treatment guidance, and communications tools to the various stakeholders in the field. 

Since 2017, IFPA and IPC, together with the International League of Dermatological Societies (ILDS), have been collaborating on the Global Psoriasis Atlas. This new partnership builds upon the mutual expertise and trust that the organizations have cultivated in that time.

Christy Langan photo             

 "Reaching out to the patient community is part of the plan for many of our projects, from the new categorization of the severity of psoriasis to telemedicine. This partnership will facilitate knowledge exchange between the medical community and the patient community."

- Christy Langan, CEO of IPC

 "This partnership is a natural move to achieve the goals in our strategy. Part of IFPA's mission is to unite, strengthen and lead the global psoriatic disease community to improve the lives of all people affected by psoriatic disease."

- Frida Dunger Johnsson, Executive Director of IFPA

Together, IPC and IFPA will work to improve the lives of those living with psoriasis and psoriatic arthritis.

About the International Psoriasis Council

Founded in 2004, the International Psoriasis Council (IPC) is a dermatologist-led, voluntary, global, nonprofit organization with a network of more than 125 psoriasis experts, thought leaders, and professionals, dedicated to improving patient care around the globe. We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Ultimately, a world without psoriasis is possible.

IPC harnesses the collective expertise of its global network of experts to educate other physicians on the range of topics related to psoriasis management. Courses are presented live via webinar or video-on-demand. IPC publishes resources, tools, and information available at no cost to clinicians to reinforce its psoriasis curriculum. Additionally, IPC conducts research in areas important to improving psoriasis care overall. These include developing a global epidemiological resource on psoriasis, reconsidering how disease severity is measured, and publishing a consensus statement on the use of telemedicine in the treatment of psoriasis.

About International Federation of Psoriatic Disease Associations

IFPA is the only global organization representing and uniting all people living with psoriatic disease – regardless of where they live, what type of psoriatic disease they have, or how it impacts their lives. IFPA is the global leader advancing psoriatic disease policy and the trusted convener of psoriatic disease stakeholders across sectors and geographies. By joining together, IFPA addresses the unmet needs of people living with psoriatic disease. Some notable actions include World Psoriasis Day every October 29th, the tri-annual World Psoriasis & Psoriatic Arthritis Conference, and the Global Psoriasis Atlas, a project of IFPA, IPC, and the International League of Dermatological Societies.

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now


on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.